Tumor Treating Fields Increases Blood-Brain Barrier Permeability and Relative Cerebral Blood Volume in Patients With Glioblastoma

Authors

Michael Iv
Lewis Naya
Sajal Sanan
Samuel L Van Buskirk
Seema Nagpal
Reena P Thomas
Lawrence D Recht
Chirag B Patel

Publication Date

2-1-2024

Journal

The Neuroradiology Journal

Abstract

BACKGROUND AND OBJECTIVE: 200 kHz tumor treating fields (TTFields) is clinically approved for newly-diagnosed glioblastoma (nGBM). Because its effects on conventional surveillance MRI brain scans are equivocal, we investigated its effects on perfusion MRI (pMRI) brain scans.

METHODS: Each patient underwent institutional standard pMRI: dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) pMRI at three time points: baseline, 2-, and 6-months on-adjuvant therapy. At each timepoint, the difference between T1 pre- versus post-contrast tumor volume (ΔT1) and these pMRI metrics were evaluated: normalized and standardized relative cerebral blood volume (nRCBV, sRCBV); fractional plasma volume (V

RESULTS: Among 13 pMRI datasets (11 nGBM, 2 recurrent GBM), therapies included temozolomide-only (

CONCLUSION: Using pMRI, we provide initial in-human validation of pre-clinical studies regarding the effects of TTFields on tumor blood volume and BBB permeability in GBM.

Keywords

Humans, Glioblastoma, Temozolomide, Blood-Brain Barrier, Cerebral Blood Volume, Reproducibility of Results, Brain Neoplasms, Magnetic Resonance Imaging, Contrast Media, blood-brain barrier, glioblastoma, magnetic resonance imaging, neuroimaging, neuro-oncology, perfusion imaging, permeability, tumor treating fields

Comments

Supplementary Materials

PMID: 37931176